135 related articles for article (PubMed ID: 35373958)
21. Initial urologic management of myelomeningocele.
Snodgrass WT; Adams R
Urol Clin North Am; 2004 Aug; 31(3):427-34, viii. PubMed ID: 15313052
[TBL] [Abstract][Full Text] [Related]
22. Urodynamic Findings and Renal Function in Children with Neurogenic Bladder after Myelomeningocele.
Korzeniecka-Kozerska A; Porowski T; Bagińska J; Wasilewska A
Urol Int; 2015; 95(2):146-52. PubMed ID: 26067248
[TBL] [Abstract][Full Text] [Related]
23. A 4-Year Prospective Urological Assessment of In Utero Myelomeningocele Repair-Does Gestational Age at Birth Have a Role in Later Neurogenic Bladder Pattern?
Leal da Cruz M; Liguori R; Garrone G; Ottoni SL; Cavalheiro S; Moron AF; Macedo A
J Urol; 2017 Jun; 197(6):1550-1554. PubMed ID: 27988193
[TBL] [Abstract][Full Text] [Related]
24. Effect of pelvic floor interferential electrostimulation on urodynamic parameters and incontinency of children with myelomeningocele and detrusor overactivity.
Kajbafzadeh AM; Sharifi-Rad L; Baradaran N; Nejat F
Urology; 2009 Aug; 74(2):324-9. PubMed ID: 19476983
[TBL] [Abstract][Full Text] [Related]
25. [Urodynamic changes after bladder augmentation surgery in paediatric patients with myelomeningocele due to neurogenic bladder].
Zaragoza Torres RI; Galarza-Flores ME; Gómez-Castellanos JC; Barrera-de León JC
Cir Cir; 2016; 84(2):115-20. PubMed ID: 26707251
[TBL] [Abstract][Full Text] [Related]
26. First 60 fetal in-utero myelomeningocele repairs at Saint Louis Fetal Care Institute in the post-MOMS trial era: hydrocephalus treatment outcomes (endoscopic third ventriculostomy versus ventriculo-peritoneal shunt).
Elbabaa SK; Gildehaus AM; Pierson MJ; Albers JA; Vlastos EJ
Childs Nerv Syst; 2017 Jul; 33(7):1157-1168. PubMed ID: 28470384
[TBL] [Abstract][Full Text] [Related]
27. Urological outcome after myelomeningocele: 20 years of follow-up.
Thorup J; Biering-Sorensen F; Cortes D
BJU Int; 2011 Mar; 107(6):994-9. PubMed ID: 20860652
[TBL] [Abstract][Full Text] [Related]
28. Factors predicting the success of intradetrusor onabotulinum toxin-A treatment in children with neurogenic bladders due to myelomeningocele: The outcomes of a large cohort.
Danacioglu YO; Keser F; Ersoz C; Polat S; Avci AE; Kalkan S; Silay MS
J Pediatr Urol; 2021 Aug; 17(4):520.e1-520.e7. PubMed ID: 33712371
[TBL] [Abstract][Full Text] [Related]
29. Fetal intervention for myelomeningocele: effect on postnatal bladder function.
Holmes NM; Nguyen HT; Harrison MR; Farmer DL; Baskin LS
J Urol; 2001 Dec; 166(6):2383-6. PubMed ID: 11696792
[TBL] [Abstract][Full Text] [Related]
30. Does surgical release of secondary spinal cord tethering improve the prognosis of neurogenic bladder in children with myelomeningocele?
Tarcan T; Onol FF; Ilker Y; Simsek F; Ozek M
J Urol; 2006 Oct; 176(4 Pt 1):1601-6; discussion 1606. PubMed ID: 16952698
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of videourodynamic study in the decision-making of surgical intervention and bladder management for neurogenic lower urinary tract dysfunction among patients with myelomeningocele.
Yu WR; Kuo HC
Int Urol Nephrol; 2022 Aug; 54(8):1815-1824. PubMed ID: 35608803
[TBL] [Abstract][Full Text] [Related]
32. Onabotulinumtoxin A for treating overactive/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele.
Marte A
Toxins (Basel); 2012 Dec; 5(1):16-24. PubMed ID: 23274271
[TBL] [Abstract][Full Text] [Related]
33. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Álvares RA; Araújo ID; Sanches MD
BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
[TBL] [Abstract][Full Text] [Related]
34. Bladder-sphincter dysfunction in myelomeningocele.
van Gool JD; Dik P; de Jong TP
Eur J Pediatr; 2001 Jul; 160(7):414-20. PubMed ID: 11475578
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
36. Can dynamic ultrasonography replace urodynamics in the follow-up of patients with myelomeningocele? A prospective concurrent study.
Bortolini T; Lucena IRS; da Silva Batezini NS; Rosito TE; Araújo T; Carneiro BB; Tavares PM; Souza PC; Neto BS
Neurourol Urodyn; 2019 Jan; 38(1):278-284. PubMed ID: 30350876
[TBL] [Abstract][Full Text] [Related]
37. Botulinum injection is useless on fibrotic neuropathic bladders.
Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
[TBL] [Abstract][Full Text] [Related]
38. Intradetrusor Injections of Botulinum Toxin Type A in Children With Spina Bifida: A Multicenter Study.
Hascoet J; Peyronnet B; Forin V; Baron M; Capon G; Prudhomme T; Allenet C; Tournier S; Maurin C; Cornu JN; Bouali O; Peycelon M; Arnaud A; Renaux-Petel M; Liard A; Karsenty G; Manunta A; Game X
Urology; 2018 Jun; 116():161-167. PubMed ID: 29522865
[TBL] [Abstract][Full Text] [Related]
39. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.
Kato T; Mizuno K; Nishio H; Yasui T; Hayashi Y
J Med Case Rep; 2021 Feb; 15(1):86. PubMed ID: 33602290
[TBL] [Abstract][Full Text] [Related]
40. Temporary perineal urethrostomy for external sphincter dilation in a male patient with high risk myelomeningocele.
Miller DC; Bloom DA; McGuire EJ; Park JM
J Urol; 2003 Oct; 170(4 Pt 2):1606-8; discussion 1608-9. PubMed ID: 14501673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
